1. Home
  2. GH vs OMAB Comparison

GH vs OMAB Comparison

Compare GH & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$102.33

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

OMAB

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

HOLD

Current Price

$107.35

Market Cap

5.3B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
OMAB
Founded
2011
1998
Country
United States
Mexico
Employees
N/A
N/A
Industry
Medical Specialities
Aerospace
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
14.1B
5.3B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
GH
OMAB
Price
$102.33
$107.35
Analyst Decision
Strong Buy
Buy
Analyst Count
21
4
Target Price
$96.48
$102.50
AVG Volume (30 Days)
1.8M
62.4K
Earning Date
02-19-2026
10-24-2025
Dividend Yield
N/A
3.97%
EPS Growth
N/A
6.38
EPS
N/A
0.75
Revenue
$902,569,000.00
$870,458,176.00
Revenue This Year
$35.00
$3.46
Revenue Next Year
$26.80
$12.24
P/E Ratio
N/A
$18.04
Revenue Growth
30.38
8.86
52 Week Low
$30.15
$68.37
52 Week High
$112.43
$116.26

Technical Indicators

Market Signals
Indicator
GH
OMAB
Relative Strength Index (RSI) 54.93 52.02
Support Level $99.82 $104.39
Resistance Level $104.75 $114.36
Average True Range (ATR) 3.20 2.86
MACD -0.56 0.09
Stochastic Oscillator 69.18 37.51

Price Performance

Historical Comparison
GH
OMAB

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.

Share on Social Networks: